Go to the profile of Epygenix Therapeutics, Inc.

Epygenix Therapeutics, Inc.

 
  • 1 (201) 940-7377
  • Networkers
  • United States of America
Go to the profile of Najoua Borkadi
Najoua Borkadi

Business Development Associate Director, University of Michigan

Go to the profile of Albany A. Cordova Martins
Albany A. Cordova Martins

Business Development Executive, Nature Publishing Group, Springer Nature

Sinergium Biotech is an Argentine biopharmaceutical company specializing in the research, development, production and marketing of high complexity vaccines and biopharmaceuticals. With unique characteristics worldwide, it carries out an innovative productive model of strategic alliances with national and international laboratories that allows: the transfer and availability of state-of-the-art technologies, autonomy in production and provision of strategic products that were previously to be imported, Generation of new sources of work with highly qualified professionals, the replacement of imports and the generation of significant export potential.
A privately held clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, is pioneering messenger RNA (mRNA)-based medicines to transform how the human body prevents and fights disease.
Qurient is a ‘Network R&D company’ mainly focuses on development of novel therapeutics from late discovery to human proof of concept. Qurient has expertise in virtual R&D project management and operates through extensive network of research organizations.
Incorporated in 2000, Chimerix is a biopharmaceutical company discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix's proprietary lipid conjugate technology has produced brincidofovir; CMX157, which was licensed to ContraVir pharmaceuticals; and earlier-stage clinical candidates. Chimerix recently announced a new clinical candidate, CMX521, for the treatment and/or prevention of norovirus. We believe that antivirals that could reduce the frequency of these and other DNA viruses and potentially avoid increasing the risk of other opportunistic infections could provide measurable clinical and pharmacoeconomic benefits for patients and the healthcare system. Through work to date, we see significant opportunities to apply the lipid conjugate technology to other disease categories that are also characterized by a need for effective treatments.
ImmuneMed, Inc. is specialized to diagnose and treat the infectious diseases using antibody and antigen discovery technologies. ImmuneMed Inc. believes that the human immune system itself is the most effective defence system of our body in curing various infectious diseases. These beliefs have been a guiding principle for the company's research over the years. Using the innate immune system, a new antiviral therapeutic has been discovered and developed an endogenous broad-spectrum antiviral drug candidate called Virus suppressing factor (VSF). ImmuneMed has been further developing VSF to humanized VSF (hzVSF) as an immunoglobulin. ImmuneMed has demonstrated the potential of hzVSF in a series of pre-clinical tests including Hepatitis B & C virus and Influenza A virus in vitro and in vivo using several animal models. ImmuneMed did toxicological test for hzVSF and has planned to manufacture GMP drug product of hzVSF in Lonza. Now ImmuneMed expects to enter a phase 1 clinical trial in 2017 in South Korea. In addition, ImmuneMed has been developed the rapid diagnostic kits using lateral flow immunochromatographic assay for early detection of acute febrile illnesses. Now ImmuneMed are developing diagnostic kits including Dengue Haemorrhagic Fever, Typhoid Fever and etc. ImmuneMed has been holding ambitions which contribute to human health to be free from infectious diseases since it was founded in 2000.
NovaBiotics Ltd is a leading clinical-stage biotechnology company focused on the design and development of first-in-class anti-infectives for difficult to treat, medically unmet bacterial and fungal diseases. The Company’s advanced portfolio of antimicrobial therapeutic candidates targets large and important markets with significant unmet clinical needs, including Lynovex (in oral and inhaled form), an orphan drug candidate for cystic fibrosis (CF), Novexatin, a potential step change therapy for onychomycosis (being co-developed with and out-licensed to Taro Pharmaceuticals) and Novamycin, a novel antifungal peptide in development for the treatment of aspergillosis, candidiasis and cryptococcosis. Novexatin and Novamycin are among the first-in-class peptide anti-infectives which the company continues to derive from its proprietary antimicrobial peptide rational drug design platform. Lynovex and Nylexa have been developed as novel antimicrobial adjunct therapies from the company's more recently established aminothiol platform. NovaBiotics has a strong portfolio of granted and pending patents which are wholly owned by the Company. NovaBiotics was founded by our CEO, Dr. Deborah O’Neil in 2004 with the goal of fully developing and realizing the therapeutic and commercial potential of innate immune system effector based antibacterials and antifungals. NovaBiotics is a privately held company, based in Aberdeen, UK & Raleigh, NC, U.S.